Inemesit Umoren, MD
Infectious Disease · Boynton Beach, FLNPI 1770639676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Cipla USA Inc. at 47.1% of the total. Reporting peaked in 2021 at $1,412 and has fallen 60.6% since, to $556 in 2025.
Across 74 payments — averaging $55.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$2K
- Janssen Products, LP$499
- Viiv Healthcare Company$338
- AbbVie$310
- Gilead$207
- Johnson & Johnson$149
- plus $666 from 9 others
What the payments were for
- Food & beverage$3,95997%
- Education$1433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 8 | $1,933 |
| Janssen Products, LP | 5 | $499 |
| Viiv Healthcare Company | 7 | $338 |
| AbbVie(2 entities) | 7 | $310 |
| Gilead | 6 | $207 |
| Johnson & Johnson | 13 | $149 |
| Insmed, Inc. | 6 | $129 |
| Merck | 7 | $120 |
| Astellas Pharma US Inc | 3 | $109 |
| AstraZeneca | 1 | $99 |
| Melinta Therapeutics, LLC | 5 | $98 |
| Paratek Pharmaceuticals, Inc. | 2 | $40 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $38 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,101 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 23 | $19,611 |
| ErtapenemErtapenem Sodium | 35 | $16,823 |
| Meropenem | 29 | $12,724 |
| Cefepime Hcl | 34 | $11,512 |
| Vancomycin Hcl | 41 | $6,022 |
| CeftriaxoneCeftriaxone Sodium | 43 | $3,186 |
| Sodium Chloride0.9 % Sodium Chloride | 62 | $2,187 |
| Cefazolin Sodium | 50 | $2,099 |
| Ciprofloxacin Hcl | 20 | $189 |
| Cefdinir | 14 | $171 |
| Doxycycline Hyclate | 16 | $122 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boynton Beach
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.